KR101364752B1 - Method for prepairing food using abalone, seaweed and wild plants - Google Patents
Method for prepairing food using abalone, seaweed and wild plants Download PDFInfo
- Publication number
- KR101364752B1 KR101364752B1 KR1020110140666A KR20110140666A KR101364752B1 KR 101364752 B1 KR101364752 B1 KR 101364752B1 KR 1020110140666 A KR1020110140666 A KR 1020110140666A KR 20110140666 A KR20110140666 A KR 20110140666A KR 101364752 B1 KR101364752 B1 KR 101364752B1
- Authority
- KR
- South Korea
- Prior art keywords
- abalone
- seaweed
- wild
- extract
- wild grass
- Prior art date
Links
- 241001474374 Blennius Species 0.000 title claims abstract description 75
- 235000013305 food Nutrition 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 20
- 241000196324 Embryophyta Species 0.000 title description 4
- 239000000284 extract Substances 0.000 claims abstract description 63
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 40
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 claims abstract description 19
- 108090000790 Enzymes Proteins 0.000 claims abstract description 19
- 241000512259 Ascophyllum nodosum Species 0.000 claims abstract description 14
- 241000195493 Cryptophyta Species 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 9
- 108091005804 Peptidases Proteins 0.000 claims abstract description 8
- 238000005406 washing Methods 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 7
- 102000035195 Peptidases Human genes 0.000 claims abstract description 6
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 230000000415 inactivating effect Effects 0.000 claims abstract description 4
- 239000002198 insoluble material Substances 0.000 claims abstract description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 6
- 241000209504 Poaceae Species 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000021419 vinegar Nutrition 0.000 claims description 4
- 239000000052 vinegar Substances 0.000 claims description 4
- 108010009355 microbial metalloproteinases Proteins 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 238000000227 grinding Methods 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 206010012289 Dementia Diseases 0.000 abstract description 13
- 230000003405 preventing effect Effects 0.000 abstract description 9
- 208000010877 cognitive disease Diseases 0.000 abstract description 8
- 239000002994 raw material Substances 0.000 abstract description 7
- 208000000044 Amnesia Diseases 0.000 abstract description 5
- 208000026139 Memory disease Diseases 0.000 abstract description 5
- 230000013016 learning Effects 0.000 abstract description 5
- 230000006984 memory degeneration Effects 0.000 abstract description 5
- 208000023060 memory loss Diseases 0.000 abstract description 5
- 238000002203 pretreatment Methods 0.000 abstract description 4
- 235000019629 palatability Nutrition 0.000 abstract description 3
- 230000006866 deterioration Effects 0.000 abstract description 2
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 240000001810 Angelica gigas Species 0.000 abstract 1
- 235000018865 Angelica gigas Nutrition 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 150000001413 amino acids Chemical class 0.000 description 12
- 241000125175 Angelica Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 10
- 239000002858 neurotransmitter agent Substances 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 8
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000011575 calcium Substances 0.000 description 7
- 229910052791 calcium Inorganic materials 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 102000012440 Acetylcholinesterase Human genes 0.000 description 6
- 108010022752 Acetylcholinesterase Proteins 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 229940022698 acetylcholinesterase Drugs 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 230000003925 brain function Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 229960003080 taurine Drugs 0.000 description 5
- 230000001256 tonic effect Effects 0.000 description 5
- 208000028698 Cognitive impairment Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000206572 Rhodophyta Species 0.000 description 3
- 206010039966 Senile dementia Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- -1 nopaadrenaline Chemical compound 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 2
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010067572 Oestrogenic effect Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 102000005158 Subtilisins Human genes 0.000 description 2
- 108010056079 Subtilisins Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001076 estrogenic effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008202 granule composition Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229940124595 oriental medicine Drugs 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
- GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 description 1
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000007862 Capsicum baccatum Nutrition 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- CUKSFECWKQBVED-INIZCTEOSA-N Decursin Chemical compound C1=CC(=O)OC2=C1C=C1C[C@H](OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-INIZCTEOSA-N 0.000 description 1
- BGXFQDFSVDZUIW-UHFFFAOYSA-N Decursinol Natural products O1C(=O)C=CC2=C1C=C1OC(C)(C)C(O)CC1=C2 BGXFQDFSVDZUIW-UHFFFAOYSA-N 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- CUKSFECWKQBVED-UHFFFAOYSA-N Grandivittin Natural products C1=CC(=O)OC2=C1C=C1CC(OC(=O)C=C(C)C)C(C)(C)OC1=C2 CUKSFECWKQBVED-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000206607 Porphyra umbilicalis Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001991 Proanthocyanidin Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001728 capsicum frutescens Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- JXZWWIMXTVJNSF-UHFFFAOYSA-N decursin Natural products CC(=CC(=O)OC1Oc2cc3OC(=O)C=Cc3cc2CC1(C)C)C JXZWWIMXTVJNSF-UHFFFAOYSA-N 0.000 description 1
- BGXFQDFSVDZUIW-LBPRGKRZSA-N decursinol Chemical compound O1C(=O)C=CC2=C1C=C1OC(C)(C)[C@@H](O)CC1=C2 BGXFQDFSVDZUIW-LBPRGKRZSA-N 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000013525 hypothesis research Methods 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940071264 lithium citrate Drugs 0.000 description 1
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 238000011302 passive avoidance test Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/40—Shell-fish
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/202—Algae extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
- A23V2250/2042—Marine animal, fish extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/28—Hydrolysis, degree of hydrolysis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 전복, 해조류 및 산야초를 이용한 식품의 제조방법에 관한 것으로, 보다 상세하게는 전복을 가수분해하여 인지기능 장애나 기억력 감퇴, 학습능력저하 예방 및 치매예방활성 또는 개선하는 효능을 갖는 전복 기능성 효소적 가수분해물을 제조하고, 그 전복의 효소적 가수분해물에 해조류와 산야초 추출물을 혼합하여 기호성을 개선시킬 수 있는 전복, 해조류 및 산야초를 이용한 식품의 제조방법에 관한 것이다.
본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법은, (a) 전복을 세척, 이물질 제거, 껍질 제거의 전처리 제1단계와, (b) 제1단계에서 분리된 가식부위를 분쇄기를 이용하여 분쇄하는 제2단계와, (c) 제2단계에서 제조한 분쇄물에 단백질 가수분해효소를 첨가하여 효소적 가수분해를 하는 제3단계와, (d) 제3단계에서 제조한 전복 효소적 가수분해물을 열처리를 통해 효소를 불활성화시킨 후 잔존하는 불용성 물질을 제거하여 전복 효소적 가수분해물을 소재화하는 제4단계와, (e) 해조류(김, 미역, 다시마)와 산야초(복분자, 당귀, 오가피) 등의 원료를 세척, 이물질 제거 전처리하는 제5단계와, (f) 제5단계의 전처리한 원료를 각각 또는 함께 10배의 물을 가하여 열수추출하는 제6단계와, (g) 제6단계에서 얻어진 추출물을 여과하고 농축 또는 건조하는 제7단계와, (h) 제4단계에서 얻은 전복 효소적 가수분해물과 제6단계에서 얻은 해조류 및 산야초 추출물을 혼합하는 제8단계를 포함하는 것을 특징으로 한다.The present invention relates to a method of manufacturing food using abalone, seaweed and wild grass, more specifically, abalone functional having the effect of hydrolyzing abalone to prevent cognitive dysfunction or memory loss, preventing learning deterioration and preventing or improving dementia The present invention relates to a method for preparing foods using abalone, seaweed and wild grass that can be prepared by enzymatic hydrolyzate and improve the palatability by mixing seaweed and wild grass extract of the abalone.
Food production method using abalone, seaweed and wild grass according to the present invention, (a) pre-treatment of washing the abalone, removing foreign substances, shell removal, and (b) the edible portion separated in the first step grinder A second step of pulverization using the second step, (c) a third step of enzymatic hydrolysis by adding a proteolytic enzyme to the pulverized product prepared in the second step, and (d) the abalone enzyme prepared in the third step A fourth step of materializing the abalone enzymatic hydrolyzate by inactivating the enzyme through heat treatment of the red hydrolyzate and removing the remaining insoluble material, and (e) seaweed (seaweed, seaweed, kelp) and wild grass (bokbunja, (5) a fifth step of pre-treatment of raw materials, such as Angelica gigas and Ogapi), and (f) a sixth step of extracting hot water by adding 10 times of water to each of the pre-treated raw materials of the fifth step or together, and (g) The extract obtained in step 6 is filtered and concentrated or dried It is characterized in that it comprises an eighth step of mixing the extracts obtained from marine algae and sanyacho seventh step and, (h) the upset enzymatic hydrolyzate and a sixth step obtained in step 4.
Description
본 발명은 전복, 해조류 및 산야초를 이용한 식품의 제조방법에 관한 것으로, 보다 상세하게는 전복을 가수분해하여 인지기능 장애나 기억력 감퇴, 학습능력저하 예방 및 치매예방활성 또는 개선하는 효능을 갖는 전복 기능성 효소적 가수분해물을 제조하고, 그 전복의 효소적 가수분해물에 해조류와 산야초 추출물을 혼합하여 기호성을 개선시킬 수 있는 전복, 해조류 및 산야초를 이용한 식품의 제조방법에 관한 것이다.The present invention relates to a method of manufacturing food using abalone, seaweed and wild grass, more specifically, abalone functional having the effect of hydrolyzing abalone to prevent cognitive dysfunction or memory loss, preventing learning deterioration and preventing or improving dementia The present invention relates to a method for preparing foods using abalone, seaweed and wild grass that can be prepared by enzymatic hydrolyzate and improve the palatability by mixing seaweed and wild grass extract of the abalone.
전복은 유용연체동물류의 원시복족목 전복과에 속하며, 해조류를 먹이로 생육하고 칼슘, 인 등의 무기질, 비타민 B1, B2 및 단백질이 풍부하며, 특히 타우린 성분이 풍부하여 간장보호, 피로회복, 심근경색 등에 대한 예방효과를 가지고 있는 고급 어패류로 우리나라에서는 예로부터 강장과 신장을 보호하며 문(입술)을 맑게 하고, 위를 열어주며, 해수(咳嗽)를 다스리고, 피로회복, 자양강장 등의 효능이 있는 것으로 알려져 있어 건강식으로 애용되고 있다. 또한 전복은 눈의 시신경 피로 증세에 탁월한 효능이 있다고 알려져 있으며, 전복의 껍질은 한방에서도 석결명(石決明)이라 하여 결막염과 백내장 등에 요긴하게 쓰이고 있다. 전복은 그 희소성으로 인하여 가공식품 관련기술은 거의 없으나 양식기술의 발달로 인하여 그 생산량이 급격하게 증가하고 있다. 저장성이 확보되고 한방약재로 활용하고자 가장 기본적인 가공방법으로 마른 전복을 가공하는 방법, 전복죽, 고추장 전복, 전복 내장 젓갈 등으로 소비가 점차 확대되고 있는 실정이다.Abalone belongs to the abalone family of the native mollusks of useful mollusks, and it is grown by feeding algae and is rich in minerals such as calcium and phosphorus, vitamin B 1 , B 2 and protein, and especially rich in taurine, soy sauce protection and fatigue recovery. It is a high-quality fish and shellfish that has a prophylactic effect against myocardial infarction. In Korea, it protects the tonic and kidneys, clears the lip, opens the stomach, controls the sea water, recovers from fatigue and nourishment tonic. It is known to be effective and is favored as a health food. In addition, abalone is known to have an excellent effect on the optic nerve fatigue symptoms, the shell of abalone is also used for conjunctivitis and cataracts because it is called Seok-myeong (石決明) in oriental medicine. Abalone has almost no processed food related technology due to its scarcity, but its production is increasing rapidly due to the development of aquaculture technology. In order to secure shelf life and to use it as a herbal medicine, consumption is gradually being expanded to the method of processing dried abalone, abalone porridge, red pepper paste abalone, and abalone gut salted seafood.
김은 홍조식물로 홍조강 원시홍조아강, 김목 김과에 속하는 해조류로서 해태(海苔) 또는 해의(海衣)라고도 불리는데 미역 및 다시마와 함께 국내의 대표적인 해조류 중의 하나이다. 김의 영양성분은 30% 이상의 단백질과 1% 이하의 지방 함량을 가지는 무기질이 풍부한 알칼리성 식품으로써 methionine, threonine, leucine, isoleucine, lysine, valine 등과 같은 필수아미노산이 많이 함유되어 있는 건강식품이다. 특히, 비타민 A, B, D, E가 풍부하며, 두뇌 발달과 밀접한 관계가 있는 것으로 알려진 비타민 B2는 다른 식물성 식품에 비해 월등히 높다. 김에는 식이섬유 함유량이 높고 동맥경화의 원인이 되는 콜레스테롤 개선효과가 우수한 다당류와 타우린이 다량 함유되어 있어 영양소와 기능성을 두루 갖춘 식품이다.Seaweed is a red algae plant and belongs to the red algae raw red algae and Kim Mok lamiaceae. It is also called Haitai or Haiui. It is one of the representative algae in Korea along with seaweed and kelp. Kim's nutritional ingredient is an alkaline food rich in minerals containing more than 30% protein and less than 1% fat. It is a health food containing a lot of essential amino acids such as methionine, threonine, leucine, isoleucine, lysine and valine. In particular, it is rich in vitamins A, B, D, and E, and known to be closely related to brain development, vitamin B 2 is much higher than other plant foods. Seaweed contains high amounts of dietary fiber and high amounts of polysaccharides and taurine, which are good at improving cholesterol, which causes arteriosclerosis.
다시마는 칼륨, 나트륨, 칼슘, 마그네슘 등 많은 알칼리성 금속이온을 풍부하게 함유하고 있어 현대인의 식생활의 균형을 유지할 수 있을 뿐만 아니라 요오드도 4,000ppm 이상을 함유하고 있는 훌륭한 무기질의 공급원이다. 또한 다시마의 조체를 구성하는 주성분의 하나인 알긴산은 식이섬유로서 기능뿐만 아니라 콜레스테롤 저하작용, 유해 중금속의 체내 흡수 방지 및 배출 등의 다양한 효과가 밝혀지고 있다. 다시마 중의 저분자 질소화합물 중의 하나인 laminine은 혈압강하작용이 있는 것으로 밝혀져 있으며 taurine도 다량 함유하고 있는 우수한 식량자원이다.Kelp is rich in many alkaline metal ions such as potassium, sodium, calcium, and magnesium, which not only helps to balance the diet of modern people, but also is a good source of minerals containing more than 4,000 ppm of iodine. In addition, alginic acid, one of the main constituents of kelp, has been found to have various effects such as cholesterol lowering function, prevention of harmful heavy metal absorption and release as well as dietary fiber. Laminine, a low-molecular nitrogen compound in kelp, has been shown to have a blood pressure-lowering effect and is an excellent food source containing a lot of taurine.
산야초는 흔히 한방에서 한약재 등으로도 사용되며 그 소재의 다양성과 기능성에 의해 치매예방 및 치료 소재개발에 관심이 집중되어 다양한 연구가 진행되고 있으며 acetylcholine esterase inhibitor, β-amyloid의 뇌 축적저해, 뇌혈류 개선, 산화적 스트레스 억제효과, estrogenic effect 등의 다양한 측면에서 연구들이 이루어지고 있다.Sanyacho is also widely used as a herbal medicine in herbal medicine, and various researches are being conducted due to its focus on developing dementia and therapeutic materials due to its diversity and functionality.In addition, acetylcholine esterase inhibitor, β-amyloid, brain accumulation and cerebral blood flow Research is being conducted on various aspects such as improvement, oxidative stress inhibitory effect and estrogenic effect.
당귀는 미나리과의 Angelica속 식물로, 줄기는 암록색, 키가 1.0∼1.5 m, 꽃은 담자색, 개화기는 8∼9월이며 우리나라와 중국 그리고 일본에서 한방약재로 사용하기 위해 재배되고 있다. 당귀는 빈혈치료, 진정작용, 항암작용, 진통억제, 상처치료, 당뇨성 고혈압 치료에 효과가 있다고 알려져 있으며, 또한 nodakentin, decursin, decursinol, umbelliferon, β-sitosterol 등 많은 기능성 성분들을 함유하고 있다. 또한 뇌실내 β-amyloid 1-42를 투여한 치매유발모델에서 당귀가 passive avoidance test에서 escape latency를 유의하게 증가시켰고 dose-response를 나타내었으며 투여기간이 길수록 높은 효과를 나타내었다. Angelica is a plant in the genus Angelica, whose stem is dark green, 1.0-1.5 m tall, the flowers are light purple, and the flowering period is from August to September. It is cultivated for use as a herbal medicine in Korea, China and Japan. Angelica is known to be effective in treating anemia, sedation, anticancer, analgesic suppression, wound healing, and diabetic hypertension. It also contains many functional ingredients such as nodakentin, decursin, decursinol, umbelliferon, and β-sitosterol. In the dementia-induced model treated with intraventricular β-amyloid 1-42, Angelica significantly increased the escape latency in the passive avoidance test, showed dose-response, and the longer the duration of administration, the higher the effect.
복분자는 장미과에 속하는 낙엽관목으로 높이가 3m에 달하며 우리나라의 제주도를 비롯한 남부지방과 중부지방의 산기슭 양지바른 곳에서 자라고, 잎은 호생하며 우상복엽이다. 산방화서는 가지 끝에 달리며 털이 있고 5~6월에 꽃이 피며, 7~8월에는 적색으로 익지만 나중에는 흑색이 된다. 일반적으로 복분자는 미성숙 과일을 말하며 한방에서는 명안, 태생, 지신, 음위, 강장, 양모 등에 사용되어 왔다. 복분자의 각 부위별 연구현황을 보면 잎을 이용하여 phenolic compound와 flavonoid를 분리동정하였고, 줄기로부터 2종의 flavan-3-ol, 1종의 proanthocyanidin과 1종의 ellagitanin을 분리하였다. 또한 항산화, 면역활성 증가, B형 간염바이러스(HBV) 억제, 항암활성, 항암 및 항스트레스효과에 관한 연구 등이 보고되었다.Bokbunja is a deciduous shrub belonging to the Rosaceae family, reaching 3m in height, growing in sunny areas at the foot of the southern and central regions, including Jeju Island, Korea. The mountain stalk is at the end of its branches, hairy, and blooms in May-June, ripens red in July-August, but later turns black. In general, bokbunja refers to immature fruit, and has been used in oriental medicine, birth, jisin, genital, tonic, and wool. According to the study of each part of bokbunja, phenolic compounds and flavonoids were identified using leaves, and two flavan-3-ols, one proanthocyanidin and one ellagitanin were isolated from the stem. In addition, studies on antioxidant, increased immune activity, hepatitis B virus (HBV) inhibition, anticancer activity, anticancer and antistress effects have been reported.
오가피는 두릅나무과에 속하는 오갈피나무 또는 기타 동속식물의 뿌리, 줄기 및 껍질로서 관상 또는 반관상 식물로 보통 길이 5~10cm, 지름 5~8mm, 두께 1mm 정도이고, 바깥 면은 황갈색-어두운 회색으로 평탄하며 군데군데 가시가 있거나 그 자국이 있고, 비교적 어린가지의 껍질에는 회백색의 반점이 있다. 오가피는 동의보감, 한약집성방, 신농본초경, 본초강목 등의 고전에 따르면 발산, 구풍작용 등의 대사촉진제로 이용되어져 왔고, 특히 자양, 강장, 강정, 음위, 진경, 근골동통, 산기 복통, 요슬동통 등의 효능이 있어 주로 강장약으로 신경통, 중풍, 고혈압, 당뇨병, 류마티스성 관절염 치료 등의 효과가 알려져 있다.Ogapi is the root, stem and bark of the algae tree or other cognate, belonging to the family Arboraceae, tubular or semi-tubular, usually 5-10 cm long, 5-8 mm in diameter, 1 mm thick, and its outer surface is tan-dark gray. It has thorns or marks in some places, and there are off-white spots on the bark of relatively young branches. Ogapi has been used as a metabolic accelerator for divergence and cleft, according to the classics such as Dongbobogam, Chinese herbal medicine cultivation, Shinnongboncho, and Herbal Wood, especially nourishment, tonic, gangjeong, sonic, Jinkyung, muscular pain, acidic abdominal pain, and painful pain. Because of the efficacy of the tonic is mainly known to treat neuralgia, stroke, hypertension, diabetes, rheumatoid arthritis and the like.
노인성치매는 심한 뇌위축과 뇌세포의 손상으로 말미암아 기억력 및 각종 인지기능이 감퇴되고 추상적인 사고판단 능력이 현격하게 저하되므로서 궁극적으로는 심각한 성격장애, 불면, 망상, 행동장애 등의 증상을 나타내게 되는 대표적인 퇴행성 만성 뇌질환이다.Geriatric dementia causes severe brain atrophy and brain cell damage, resulting in a decrease in memory and cognitive function, and a dramatic decrease in abstract thinking. It is a representative degenerative chronic brain disease.
그러나 노인성치매는 질병의 정확한 원인이 제대로 규명되지 못하고 있는 까닭으로 항정신성약물(antipsychotics), 항우울제(antidepressant), 항불안제, 항경련제(anticonvulsant), 뇌기능개선제(nootropics), 신경전달물질의 대사에 관여하는 효소차단제(enzyme blocker), 칼슘차단제(Ca-blocker) 등의 약제들을 환자의 상태에 따라 적절하게 처치하는 대증요법만이 최선의 방법으로 알려져 있다. 노인성치매로부터 유발되는 기억력상실, 학습력 저하 등 각종 인지기능장애는 주로 대뇌 기저부의 acetylcholine성 신경세포의 손상으로부터 기인되다는 연구가설에 의거하여 무스카린성 acetylcholine 수용체에 대한 효능제, acetylcholine 생성촉진제, acetylcholinesterase(AChE) 저해제 등 여러 가지 작용기전에 따라 acetylcholine성 신경세포의 기능을 강화시켜줄 수 있는 많은 약물들이 연구개발되어 지고 있다. 노인성치매 개선제로 활발하게 연구개발되어 지고 있는 분야는 AChE 저해제에 관한 연구로서 현재 시판되는 tacrine, rivastigmine, donepezil, galantamine 등의 약제들은 모두 acetylcholinesterase 저해효과를 약효의 근간으로 삼고 있다.However, senile dementia is involved in the metabolism of antipsychotics, antidepressants, antianxiety agents, anticonvulsants, nootropics, and neurotransmitters because the exact cause of the disease is not well understood. The only symptomatic therapy is to treat drugs such as enzyme blockers and calcium blockers according to the condition of the patient. Agonists for the muscarinic acetylcholine receptor, acetylcholine production promoter, and acetylcholinesterase based on the research hypothesis that various cognitive dysfunctions such as memory loss and learning loss caused by senile dementia are mainly caused by damage of acetylcholine neurons in the base of cerebral base. Many drugs have been researched and developed to enhance the function of acetylcholine neurons according to various mechanisms of action such as (AChE) inhibitors. The active research and development of senile dementia improvers is the study of AChE inhibitors. All currently available drugs such as tacrine, rivastigmine, donepezil, and galantamine are based on acetylcholinesterase inhibitory effects.
본 발명의 상기와 같은 점을 인식하여 안출된 것으로, 본 발명의 목적은 전복을 효소적 가수분해하여 인지기능 장애나 기억력 감퇴, 학습능력 저하를 예방 또는 개선하는 효능을 가진 인체에 무해한 전복 효소적 가수분해물을 제조하고 그 유효성분에 김, 다시마 추출물과 당귀, 복분자, 오가피 추출물을 혼합하여 인지기능장애,치매 예방 및 개선용 기능성 식품을 제조할 수 있는 전복, 해조류 및 산야초를 이용한 식품의 제조방법을 제공하기 위한 것이다.Recognized as described above of the present invention, the object of the present invention is the abalone enzymatic harmless to the human body having the effect of preventing or improving cognitive impairment or memory loss, lowering of learning ability by enzymatic hydrolysis of abalone. Method of preparing foods using abalone, seaweed and wild grass that prepare hydrolysates and prepare functional foods for the prevention and improvement of cognitive impairment, dementia by mixing seaweed, kelp extract, Angelica, bokbunja, and ogapi extract with the active ingredients It is to provide.
상기와 같은 목적을 달성하기 위하여 본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법은, (a) 전복을 세척, 이물질 제거, 껍질 제거의 전처리 제1단계와, (b) 제1단계에서 분리된 가식부위를 분쇄기를 이용하여 분쇄하는 제2단계와, (c) 제2단계에서 제조한 분쇄물에 단백질 가수분해효소를 첨가하여 효소적 가수분해를 하는 제3단계와, (d) 제3단계에서 제조한 전복 효소적 가수분해물을 열처리를 통해 효소를 불활성화시킨 후 잔존하는 불용성 물질을 제거하여 전복 효소적 가수분해물을 소재화하는 제4단계와, (e) 김, 미역 및 다시마가 포함된 해조류와 복분자, 당귀 및 오가피가 포함된 산야초 각각을 세척, 이물질 제거 전처리하는 제5단계와, (f) 제5단계의 전처리한 해조류와 산야초를 각각 또는 함께 10배의 물을 가하여 열수추출하는 제6단계와, (g) 제6단계에서 얻어진 추출물을 여과하고 농축 또는 건조하는 제7단계와, (h) 제4단계에서 얻은 전복 효소적 가수분해물과 제7단계에서 얻은 해조류 및 산야초 추출물을 혼합하는 제8단계를 포함하는 것을 특징으로 한다.Food production method using abalone, seaweed and wild grass according to the present invention in order to achieve the above object, (a) pre-treatment of washing the abalone, removing foreign substances, shell removal, and (b) the first step A second step of pulverizing the decorated site separated in step 2 using a grinder, (c) a third step of enzymatic hydrolysis by adding a proteolytic enzyme to the pulverized product prepared in the second step, and (d) A fourth step of materializing the abalone enzymatic hydrolyzate by inactivating the enzyme by heat treatment of the abalone enzymatic hydrolyzate prepared in the third step and removing the remaining insoluble material, and (e) laver, seaweed and kelp Seaweed and bokbunja, and the wild grasses containing the Angelica and Ogapi containing the fifth step of washing, removing foreign matters, and (f) hot water by adding 10 times the water or each of the pre-treated seaweeds and wild grasses of the fifth step 6th to extract Step 7, (g) the seventh step of filtration and concentration or drying the extract obtained in the sixth step, and (h) mixing the abalone enzymatic hydrolyzate obtained in the fourth step and the seaweed and wild grass extract obtained in the seventh step And an eighth step.
또한, 본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법은, 상기 제3단계는, 상기의 단백질 가수분해효소로 알카라제, 뉴트라제 프로타멕스, 플라보자임으로 이루어진 군에서 선택된 어느 하나 이상의 효소를 이용하고, 상기 제6단계는, 해조류와 산야초 추출물은 121℃에서 열수추출을 하는 것을 특징으로 한다.In addition, the method of preparing food using abalone, seaweed and wild grass according to the present invention, wherein the third step is any one selected from the group consisting of alkalase, neutrase protamex, flavozyme as the protease Using one or more enzymes, the sixth step, seaweed and wild grass extract is characterized in that the hot water extraction at 121 ℃.
또한, 본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법은, 상기 제8단계는 전복 효소적 가수분해물과 해조류 및 산야초 추출물을 혼합하여 액상, 과립제, 환제, 정제 중 어느 하나의 형태로 제조하는 것을 특징으로 한다.In addition, the method of manufacturing food using abalone, seaweed and wild grass according to the present invention, the eighth step is mixed with abalone enzymatic hydrolyzate and seaweed and wild grass extract in the form of liquid, granules, pills, tablets It is characterized by manufacturing.
상기와 같은 구성에 의하여 본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법은, 인지기능 장애나 기억력 감퇴, 학습능력 저하 및 치매의 예방 또는 개선하는 효능을 가진 전복 가수분해물과 해조류, 산야초 추출물을 제조하고 그 유효성분을 함유하는 치매 예방활성을 갖는 기능성 식품을 제조할 수 있는 장점을 갖는다.The method for producing food using abalone, algae and wild grass according to the present invention according to the above configuration, abalone hydrolyzate and algae, wild seaweed having the effect of preventing or improving cognitive impairment or memory loss, learning ability and dementia It has the advantage of preparing an extract and a functional food having dementia preventing activity containing the active ingredient.
도 1은 본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법의 흐름을 도시한 도면
도 2는 전복, 해조류 및 산야초를 이용한 식품의 제조방법에서 전복 효소적 가수분해물과 해조류 및 산야초 추출물의 항산화 활성을 나타낸 도면
도 3은 본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법에 따라 전복의 효소적 가수분해물과 해조류 및 산야초 추출물을 이용하여 제조한 식품(조성물)의 항치매예방 활성을 나타낸 도면1 is a view showing a flow of a method of manufacturing food using abalone, seaweed and wild grass according to the present invention
2 is a diagram showing the antioxidant activity of the abalone enzymatic hydrolyzate and seaweed and wild grass extract in the method of preparing food using abalone, seaweed and wild grass
3 is a view showing the anti-dementia prevention activity of food (composition) prepared by using the enzymatic hydrolyzate and seaweed and wild grass extract of abalone according to the method of preparing food using abalone, seaweed and wild grass according to the present invention
전복은 아미노산의 함량이 높은데 특히 글루타민산, 아르기닌, 히스티딘, 티로신, 타우린 등의 함량이 높고, 비타민, 칼슘, 인, 철, 요오드 등의 미네랄이 풍부하여 성장기 어린이나 임산부, 노약자의 건강식으로 좋은 음식이다.Abalone has a high content of amino acids, especially glutamic acid, arginine, histidine, tyrosine and taurine, and is rich in vitamins, calcium, phosphorus, iron and iodine, and is a healthy food for growing children, pregnant women, and the elderly. .
산야초는 흔히 한방에서 한약재 등으로도 사용되며 그 소재의 다양성과 기능성에 의해 치매예방 및 치료 소재개발에 관심이 집중되어 다양한 연구가 진행되고 있으며 acetylcholine esterase inhibitor, β-amyloid의 뇌 축적저해, 뇌혈류 개선, 산화적 스트레스 억제효과, estrogenic effect 등의 다양한 효과가 입증되고 있다.Sanyacho is also widely used as a herbal medicine in herbal medicine, and various researches are being conducted due to its focus on developing dementia and therapeutic materials due to its diversity and functionality.In addition, acetylcholine esterase inhibitor, β-amyloid, brain accumulation and cerebral blood flow Various effects such as improvement, oxidative stress inhibitory effect and estrogenic effect have been demonstrated.
해조류는 식이섬유의 함량이 높고 미네랄과 기능성을 가진 다당류와 이들의 생리적 작용으로 콜레스테롤 저하, 암, 당뇨, 비만, 변비예방 등 기능성연구와 활용도가 계속적으로 증가하고 있다. Seaweeds have high levels of dietary fiber, minerals and functional polysaccharides, and their physiological effects continue to increase functional research and utilization, including lowering cholesterol, preventing cancer, diabetes, obesity, and constipation.
현재 알려져 있는 신경전달물질에는 아미노산 그 자체(글루타민산, 글리신, γ-아미노낙산(GABA), 타우린 등), 아민류(도파민, 노프아드레날린, 세로토닌, 아세틸콜린 등)와 펩타이드류(엔돌핀, 바소프레신 등) 기체물질(일산화질소, 일산화탄소) 등이 있다. 아미노산은 뇌 내의 신경전달물질의 합성원료로서 집중력, 인지기능 등에 크게 영향을 준다. 티로신은 뇌를 흥분시키는 카테콜 아민류의 원료이고 스트레스 환경 하에서 피로와 졸음을 감소시켜 작업 효율을 상승시킨다는 것이 보고되었다. 히스티딘은 히스타민의 원료이고, 각성에 관여하는 히스타민 신경계를 활성화 하여, 졸음을 방지하는 가능성이 있고, 분지쇄 아미노산(류신, 발린, 이소류신 BCAA)은 다른 방향족 아미노산의 취입을 저해하고 졸음의 원인인 세로토닌의 생성을 억제하여 집중력을 지속시키는 것이 기대되는 아미노산이다.Currently known neurotransmitters include amino acids themselves (glutamic acid, glycine, γ-aminobutyric acid (GABA), taurine, etc.), amines (dopamine, nopaadrenaline, serotonin, acetylcholine, etc.) and peptides (endorphins, vasopressin, etc.). Substances (nitrogen monoxide, carbon monoxide). Amino acids are a synthetic material of neurotransmitters in the brain and greatly affect concentration and cognitive function. It has been reported that tyrosine is a source of catechol amines that excite the brain and increases work efficiency by reducing fatigue and drowsiness under stress conditions. Histidine is a raw material of histamine, and it activates the histamine nervous system involved in arousal, which may prevent drowsiness. Branched-chain amino acids (leucine, valine, isoleucine BCAA) inhibit serotonin, which inhibits the intake of other aromatic amino acids and causes drowsiness. It is an amino acid that is expected to sustain the concentration by inhibiting the production of.
뇌내에 있어서는, 신경전달물질의 양이 균형을 유지하도록 하여 건강한 뇌기능이 유지되어 진다. 이 균형을 유지하기 위해서는 필요에 따라 뇌내로 전달물질이 빠르게 공급되게 하지 않으면 안된다. 만약에 공급이 부족하다면 신경 시그널이 순조롭게 전해지지 않아 다양한 신경이상이 발생하기도 하기 때문에 아미노산의 섭취는 뇌 기능을 유지하기 위해서도 필요하다.In the brain, the amount of neurotransmitters is balanced to maintain healthy brain function. In order to maintain this balance, it is necessary to ensure that the delivery material is quickly supplied into the brain as needed. If the supply is insufficient, the intake of amino acids is also necessary to maintain brain function because nerve signals are not transmitted smoothly and various neurological abnormalities occur.
본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법에 있어서 전복 효소적 가수분해물은 전복 세척 및 전처리, 효소처리, 효소불활성화, 여과, 농축 또는 건조하는 단계로 이루어진 공정으로부터 수득할 수 있으다. 또하나 해조류 및 산야초의 열수 추출물은 원료 세척 및 전처리, 열수추출, 여과, 농축 또는 건조하는 단계로 이루어진 공정으로부터 수득할 수 있다.Abalone enzymatic hydrolyzate in the method of preparing food using abalone, seaweed and wild grass according to the present invention can be obtained from the process consisting of abalone washing and pretreatment, enzyme treatment, enzyme inactivation, filtration, concentration or drying. All. In addition, the hot water extract of seaweed and wild grass can be obtained from the process consisting of raw material washing and pretreatment, hot water extraction, filtration, concentration or drying.
구체적으로, 본 발명에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법은 다음과 같다. Specifically, a method of preparing food using abalone, seaweed and wild grass according to the present invention is as follows.
도 1은 본 발명의 일실시예에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법의 흐름을 도시한 도면으로서, 도 1을 참조하면, 본 발명의 일실시예에 따른 전복, 해조류 및 산야초를 이용한 식품의 제조방법은,1 is a view showing the flow of a method of manufacturing food using abalone, seaweed and wild grass according to an embodiment of the present invention, referring to Figure 1, abalone, seaweed and wild grass according to an embodiment of the present invention The manufacturing method of the used food,
(a)전복을 세척, 이물질 제거, 껍질 제거의 전처리 제1단계.(a) Pre-treatment of washing the abalone, removing foreign matters and removing the shells.
(b) 제1단계에서 분리된 가식부위를 분쇄기를 이용하여 분쇄하는 제2단계.(b) a second step of grinding the decorative part separated in the first step by using a grinder.
(c) 제2단계의 분쇄물에 단백질 가수분해효소를 첨가하여 효소적 가수분해를 하는 제3단계.(c) a third step of enzymatic hydrolysis by adding proteolytic enzyme to the milled product of the second step.
상기의 단백질 가수분해효소는 알카라제를 사용하며, 뉴트라제 프로타멕스, 플라보자임으로 이루어진 군에서 선택된 1종 또는 2종 이상의 효소를 이용할 수 있다.The proteolytic enzyme uses an alkalase, and one or two or more enzymes selected from the group consisting of Neutrase protamex and flavozyme can be used.
(d) 제3단계에서 제조한 전복 효소적 가수분해물을 열처리를 통해 효소를 불활성화시킨 후 잔존하는 불용성 물질을 제거하여 전복 효소적 가수분해물을 소재화하는 제4단계.(d) a fourth step of materializing the abalone enzymatic hydrolyzate by inactivating the enzyme by heat treatment of the abalone enzymatic hydrolyzate prepared in the third step to remove the remaining insoluble material.
(e) 해조류(김, 미역, 다시마)와 산야초(복분자, 당귀, 오가피) 등의 원료를 세척, 이물질 제거 전처리하는 제5단계.(e) Fifth step of pretreatment to remove raw materials such as seaweed (seaweed, seaweed, kelp) and wild grass (bokbunja, Angelica, Ogapi).
(f) 제5단계의 전처리한 원료를 각각 또는 함께 10배의 물을 가하여 열수추출하는 제6단계.(f) Sixth step of extracting hot water by adding ten times of water to each or together the pretreated raw material of the fifth step.
(g) 제6단계에서 얻어진 추출물을 여과하고 농축 또는 건조하는 제7단계.(g) a seventh step of filtering and concentrating or drying the extract obtained in the sixth step.
(h) 제4단계에서 얻은 전복 효소적 가수분해물과 제7단계에서 얻은 해조류 및 산야초 추출물을 혼합하는 제8단계를 포함하는 것을 특징으로 한다.(h) characterized in that it comprises an eighth step of mixing the abalone enzymatic hydrolyzate obtained in the fourth step and the seaweed and wild grass extract obtained in the seventh step.
본 발명에 따른 전복 효소적 가수분해물과 해조류와 산야초 추출물을 이용한 치매예방 활성의 기능성 식품의 제조방법은 상기의 효소적 가수분해물과 추출물로 그 제형이 액상, 과립, 정제, 환제 중 어느 하나의 형태로 제조하는 것을 특징으로 한다.Method for producing a functional food of dementia prevention activity using the abalone enzymatic hydrolyzate and seaweed and wild vinegar extract according to the present invention is the above-described enzymatic hydrolyzate and extract of the form of any one of liquid, granules, tablets, pills It is characterized in that the manufacturing.
또한, 본 발명은 상기 전복 효소적 가수분해물과 해조류 및 산야초 추출물의 뇌기능 신경전달물질 분해효소 저해활성과 항산화활성이 우수한 것을 확인하였다.In addition, the present invention was confirmed that the brain function neurotransmitter inhibitory activity and antioxidant activity of the abalone enzymatic hydrolyzate and seaweed and wild grass extract.
이하에서는 실시예를 참조하여 전복 효소적 가수분해물의 제조방법, 해조류 및 산야초 추출물의 제조방법 및 전복, 해조류 및 산야초를 이용한 식품의 제조방법을 상세하게 설명한다.Hereinafter, a method for preparing abalone enzymatic hydrolyzate, a method for preparing seaweed and wild grass extract, and a method for preparing food using abalone, seaweed and wild grass will be described in detail.
<실시예 1> 전복 효소적 가수분해물의 제조Example 1 Preparation of Abalone Enzymatic Hydrolyzate
본 발명의 전복 효소적 가수분해물의 제조방법은 다음과 같다. 전복을 세척하고 껍질을 제거하여 육과 내장을 함께 1kg 당 800mL의 증류수를 첨가하여 육분쇄기로 완전 분쇄하고, 상기 분쇄물에 1.2g의 단백질 분해효소인 알카라제 효소(Alcalase enzyme)를 첨가하여 60℃ 교반 배양기에서 4시간 동안 반응시켜 효소적 가수분해물을 수득하였다. 상기 수득된 가수분해물을 90℃에서 15분간 가열하여 알칼라제 효소의 활성을 불활성화시킨 다음, 불용물을 제거하기 위하여 3,000rpm으로 원심 분리하고 여과하여 상등액만을 수득하였다. 상기 상등액을 다시 90℃에서 20분간 가열 처리한 것을 농축하여 사용하거나 건조하여 기능성 식품제조의 소재로 하였다.The preparation method of the abalone enzymatic hydrolyzate of the present invention is as follows. Wash the abalone and remove the shells, add 800 mL of distilled water per 1 kg of meat and intestine together, then grind completely with a meat grinder, and add 1.2 g of protease, Alcalase enzyme, The reaction was carried out for 4 hours in a stirred incubator to obtain an enzymatic hydrolyzate. The obtained hydrolyzate was heated at 90 ° C. for 15 minutes to inactivate the activity of the alcalase enzyme, and then centrifuged at 3,000 rpm and filtered to remove insolubles, thereby obtaining only a supernatant. The supernatant was heat-treated at 90 ° C. for 20 minutes to be concentrated or used to prepare a functional food material.
<실시예 2> 전복 열수추출물의 제조Example 2 Preparation of Abalone Hot Water Extract
전복 효소적 가수분해물과 비교하기 위한 열수추출물의 제조는 다음과 같다. 생전복을 세척하고 육과 내장을 함께 사용한 것으로 육분쇄기를 이용하여 분쇄한 다음 물 1 L에 대해 전복 분쇄물을 250 g을 추출기에 넣고, 추출온도는 120℃, 추출기 압력은 1.0 kgf/cm2의 추출조건에서 3시간 추출한 다음 여과하여 추출물을 제조하였다.Preparation of hot water extract for comparison with the abalone enzymatic hydrolyzate is as follows. The fresh abalone was washed and ground together with meat and intestine, and then ground using a grinder. 250 g of abalone crushed powder was added to the extractor for 1 L of water, and the extraction temperature was 120 ° C. and the extractor pressure was 1.0 kgf / cm 2 . Extraction was performed by extracting the mixture for 3 hours under filtration and filtering.
<실시예 3> 해조류 추출물의 제조Example 3 Preparation of Seaweed Extract
본 발명에서 해조류 추출물의 제조방법은 다음과 같다. 해조류(김, 미역, 다시마)의 이물질을 제거하고 1kg 당 10L의 정제수를 첨가하여 121℃에서 3시간 열수추출 한다. 열수추출 한 것을 여과기를 사용하여 여과하고 감압하에서 농축시키거나 건조시켜 해조류 추출물을 제조하였다.The preparation method of the seaweed extract in the present invention is as follows. Remove foreign substances of seaweed (seaweed, seaweed, kelp) and add hot water of 10L per 1kg to extract hot water at 121 ℃ for 3 hours. The hot water extract was filtered using a filter and concentrated or dried under reduced pressure to prepare an algae extract.
<실시예 4> 산야초 추출물의 제조Example 4 Preparation of Sanyacho Extract
본 발명의 산야초 추출물의 제조방법은 다음과 같다. 복분자, 당귀, 오가피 등의 산야초는 이물질을 제거하고 1kg 당 10L의 정제수를 첨가하여 121℃에서 3시간 열수추출 한다. 열수추출 한 것을 여과기를 사용하여 여과하고 감압하에서 농축시키거나 건조시켜 산야초 추출물을 제조하였다.The production method of wild vinegar extract of the present invention is as follows. Sanyacho, such as bokbunja, Angelica, and Ogapi, removes foreign substances and adds 10L of purified water per 1kg to extract hot water at 121 ° C for 3 hours. The hot water extracted was filtered using a filter, and concentrated or dried under reduced pressure to prepare a wild leaf extract.
<실시예 5> 항산화활성 측정Example 5 Antioxidant Activity
전복 효소적 가수분해물과 해조류와 산야초 열수추출물에 대한 항산화활성은 다음과 같이 측정하였다. 각각의 추출물 또는 효소적 가수분해물 0.4 mL씩을 시험관에 취하고 0.1 M DPPH에탄올 용액 1.6 mL씩과 혼합하여 암소에서 10분간 반응 시킨 후 용액의 흡광도의 변화를 517nm에서 측정하였다. 측정된 흡광도는 아래 식에 따라 계산하여 자유유리기 제거능으로 표시하여 항산화활성을 비교하였다. 비교 결과는 도면 2와 같다. 즉, 전복 효소분해물은 93.4%, 김 열수추출물 54.5%, 미역 45.3%, 다시마 44.7% 였고, 복분자 91.3%, 당귀 42.2%, 오가피 38.7%의 항산화활성이 나타났다.Antioxidant activity of the abalone enzymatic hydrolyzate, seaweed and wild vinegar hot water extract were measured as follows. 0.4 mL of each extract or enzymatic hydrolyzate was taken in a test tube, mixed with 1.6 mL of 0.1 M DPPH ethanol solution for 10 minutes in the dark, and the change in absorbance of the solution was measured at 517 nm. The measured absorbances were calculated according to the following equation and expressed as free free radical scavenging ability to compare antioxidant activity. The comparison result is shown in FIG. In other words, the abalone enzyme was 93.4%, seaweed hot water extract 54.5%, seaweed 45.3%, kelp 44.7%, bokbunja 91.3%, Angelica 42.2%, Ogapi 38.7%.
항산화활성(%) = 100- (공시험의 흡광도 - 시료의 흡광도)×100/공시험의 흡광도)Antioxidant activity (%) = 100- (absorbance of blank test-absorbance of sample) × 100 / absorbance of blank test)
<실시예 6> 치매예방 뇌기능 신경전달물질 분해효소 저해활성 측정Example 6 Determination of Brain Function Neurotransmitter Degrading Enzyme Inhibition of Dementia
전복 효소적 가수분해물의 인지기능장애 예방활성 측정을 위해 뇌기능 신경전달물질 분해효소 저해활성을 측정하였다. 즉, Acetylcholinesterase(AChE) 저해효과는 acetylthiocholine을 기질로 하고 전기뱀장어에서 추출한 AChE(E.C. 3.1.1.7)를 이용하여 상법에 따라 측정하였다. 즉 choline acetyltransferase(ChAT)가 가수분해 되면 thiocholine이 생성되는데 이 화합물이 DTNB와 반응해 새로운 dithio 화합물과 2-니트로벤조산의 thio 음이온을 만든다. 이렇게 생성된 이 음이온은 UV에 정확하게 검출되기 때문에 UV에 의해 이 음이온의 생성속도를 측정함으로써 효소의 활성을 측정할 수 있다.In order to measure the cognitive impairment preventive activity of the abalone enzymatic hydrolyzate, brain neurotransmitter inhibitor activity was measured. In other words, Acetylcholinesterase (AChE) inhibition effect was measured according to the conventional method using AChE (E.C. 3.1.1.7) extracted from eel with acetylthiocholine as a substrate. Hydrolysis of choline acetyltransferase (ChAT) produces thiocholine, which reacts with DTNB to form new dithio compounds and thio anions of 2-nitrobenzoic acid. Since the anion thus produced is accurately detected by UV, the activity of the enzyme can be measured by measuring the production rate of this anion by UV.
치매예방 뇌기능 신경전달물질 분해효소 저해활성 측정결과 전복 열수추출물 보다 효소적 가수분해물에서 저해효과가 높은 것으로 나타났으며, 전복 효소분해물과 해조류 및 산야초 추출물을 혼합한 것에서도 전복 열수추출물 보다 우수한 것으로 나타났다.Determination of brain function neurotransmitter degrading enzyme activity of dementia showed higher inhibitory effect on enzymatic hydrolyzate than abalone hot water extract, and even better than abalone hot water extract when mixed with abalone enzyme digest, seaweed and wild grass extract. appear.
<실시예 7> 아미노산 함량 측정Example 7 Determination of Amino Acid Content
전복 열수추출물과 효소분해물의 아미노산을 분석하여 비교한 결과를 표 1에 나타내었다. 아미노산은 시료 5g을 취하여 70% ethanol을 50 mL 가하여 환류냉각장치에 연결하여 100℃에서 1시간 가열 환류시킨 후 여과하였다. 여액을 40℃이하에서 2~3 mL까지 감압농축시키고 농축액과 농축수기는 소량의 증류수로 세척하여 분액깔대기로 옮긴 후 diethyl ether 20 mL를 가해 2회 탈지 시킨 하층을 농축수기로 옮겨 농축, 건고시켰다. 건고시킨 시료용액을 lithium citrate 완충용액(pH 2.2)으로 용해하고 25mL로 정용한 것을 아미노산자동분석기로 분석하였다. 분석한 결과 아미노산 함량은 표 1과 같다.Table 1 shows the results of analyzing the amino acids of the abalone hydrothermal extract and enzyme digestion. 5g of the amino acid was added to 50 mL of 70% ethanol was added to the reflux condenser and heated to reflux at 100 ℃ for 1 hour and filtered. The filtrate was concentrated under reduced pressure to 2 to 3 mL under 40 ° C, the concentrate and the concentrated water were washed with a small amount of distilled water, transferred to a separatory funnel, and 20 mL of diethyl ether was added to the bottom layer to be concentrated and dried. . The dried sample solution was dissolved in lithium citrate buffer (pH 2.2), and the volume was 25 mL and analyzed using an automatic amino acid analyzer. The amino acid content of the analysis is shown in Table 1.
<전복 열수추출물과 효소분해물의 아미노산 함량(mg/100g)>
<Amino Acid Content of Abalone Hot Water Extract and Enzyme Degradation (mg / 100g)>
<실시예 8> 전복과 해조류, 산야초를 이용한 기능성 식품의 제조Example 8 Preparation of Functional Food Using Abalone, Seaweed, and Wild Grass
제조예 1 : 전복과 해조류, 산야초를 이용한 액상 조성물 제조Preparation Example 1 Preparation of Liquid Composition Using Abalone, Seaweed, and Wild Grass
전복 효소적 가수분해물 및 해조류와 산야초 열수추출물을 상기의 방법으로 제조하고, 혼합탱크에서 혼합한다. 조성물의 배합비율은 전복 효소적 가수분해물 40%, 팔라티노스 1%, 해조칼슘 0.5%, 비타민 C 0.5%, 다시마 추출물 10%, 김 추출물 8%, 미역 추출물 8%, 당귀 추출물 10%, 복분자 추출물 10%, 오가피 추출물 10%, 감초 추출물 1.5%, 자몽종자 추출물 0.5%로 혼합하여 제조하였다. 각각의 성분들이 잘 혼합되도록 교반하면서 혼합하고 여과와 살균과정을 거쳐 통상의 레토르트 파우치 또는 PET 용기, 유리병에 포장하여 제조하였다.Abalone enzymatic hydrolyzate and seaweed and Sanyacho hot water extract are prepared by the above method and mixed in a mixing tank. Composition ratio of the composition is abalone
제조예 2 : 전복과 해조류, 산야초를 이용한 환제 조성물 제조Preparation Example 2: Preparation of pill composition using abalone, seaweed, and wild grass
환제 조성물의 제조는 전복 효소적 가수분해물 40%, 팔라티노스 2%, 해조칼슘 0.5%, 비타민 C 0.5%, 다시마 추출물 분말 1%, 김 추출물 분말 1%, 미역 추출물 분말 1%, 당귀 추출물 분말 1%, 복분자 추출물 분말 2%, 오가피 추출물 분말 1%, 현미 분말 30%, 맥주효모 10%, 포도당 10%를 혼합기에서 혼합하고 환 자동제조기를 이용하여 성형한 다음 건조하여 환제를 제조하였다.Preparation of the pill composition is 40% abalone enzymatic hydrolyzate, 2% palatinose, 0.5% algae calcium, 0.5% vitamin C, kelp extract powder 1%, seaweed extract powder 1%, seaweed extract powder 1%, donkey extract powder 1 %, Bokbunja extract powder 2%, Ogapi extract powder 1%,
제조예 3 : 전복과 해조류, 산야초를 이용한 과립제 조성물 제조Preparation Example 3 Preparation of Granule Composition Using Abalone, Seaweed, and Wild Grass
과립제 조성물의 제조는 전복 효소적 가수분해물 40%, 팔라티노스 2%, 해조칼슘 0.5%, 비타민 C 0.5%, 다시마 추출물 분말 1%, 김 추출물 분말 1%, 미역 추출물 분말 1%, 당귀 추출물 분말 1%, 복분자 추출물 분말 2%, 오가피 추출물 분말 1%, 현미 분말 30%, 맥주효모 10%, 포도당 10%를 혼합기에서 혼합하고 원통형 과립기를 이용하여 성형한 다음 건조하고 정선하여 과립제를 제조하였다.Preparation of granule composition is 40% abalone enzymatic hydrolyzate, 2% palatinose, 0.5% algae calcium, 0.5% vitamin C, kelp extract powder 1%, seaweed extract powder 1%, seaweed extract powder 1%, donkey extract powder 1 %, Bokbunja extract powder 2%, Ogapi extract powder 1%,
상기의 각각의 조성물에 포함된 첨가물의 조성비는 비교적 건강식품에 적합한 성분을 바람직하게 실시한 예로 혼합조성 하였지만, 그 배합비를 임의로 변경하여 실시하여도 무방하며, 기타 다른 원료도 통상의 방법에 따라 식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the additives included in each of the above compositions was preferably mixed with an example of a suitable ingredient for health food, the composition ratio may be arbitrarily changed, and other raw materials may be prepared according to a conventional method. It can be used for manufacture.
본 발명은 전복을 효소적 가수분해물을 제조하고, 제조된 가수분해물에서 치매예방의 뇌기능 신경전달물질 분해효소 저해활성 및 항산화활성의 효능이 있음을 확인하고, 해조류 추출물과 산야초 추출물의 유효성분과 기호성이 우수한 인지기능장애 예방 또는 개선용의 기능성 식품을 얻을 수 있음을 확인하였다.The present invention is to prepare an enzymatic hydrolyzate abalone, confirm that the prepared hydrolyzate is effective in inhibiting dementia prevention neurotransmitter degrading enzyme and antioxidant activity, and active ingredient and palatability of seaweed extract and wild vegetable extract It was confirmed that this excellent functional food for preventing or improving cognitive dysfunction could be obtained.
앞에서 설명되고 도면에 도시된 전복, 해조류 및 산야초를 이용한 식품의 제조방법은 본 발명을 실시하기 위한 하나의 실시예에 불과하며, 본 발명의 기술적 사상을 한정하는 것으로 해석되어서는 안된다. 본 발명의 보호범위는 이하의 특허청구범위에 기재된 사항에 의해서만 정하여지며, 본 발명의 요지를 벗어남이 없이 개량 및 변경된 실시예는 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 자명한 것인 한 본 발명의 보호범위에 속한다고 할 것이다.The method of preparing food using abalone, algae and wild grass described above and shown in the drawings is only one embodiment for carrying out the present invention, and should not be construed as limiting the technical idea of the present invention. The scope of protection of the present invention is defined only by the matters set forth in the claims below, and the embodiments which have been improved and changed without departing from the gist of the present invention will be apparent to those skilled in the art. It will be said to belong to the protection scope of the present invention.
Claims (3)
(b) 제1단계에서 분리된 가식부위를 분쇄기를 이용하여 분쇄하는 제2단계와,
(c) 제2단계에서 제조한 분쇄물에 단백질 가수분해효소를 첨가하여 효소적 가수분해를 하는 제3단계와,
(d) 제3단계에서 제조한 전복 효소적 가수분해물을 열처리를 통해 효소를 불활성화시킨 후 잔존하는 불용성 물질을 제거하여 전복 효소적 가수분해물을 소재화하는 제4단계와,
(e) 김, 미역 및 다시마가 포함된 해조류와 복분자, 당귀 및 오가피가 포함된 산야초 각각을 세척, 이물질 제거 전처리하는 제5단계와,
(f) 제5단계의 전처리한 해조류와 산야초를 각각 또는 함께 10배의 물을 가하여 열수추출하는 제6단계와,
(g) 제6단계에서 얻어진 추출물을 여과하고 농축 또는 건조하는 제7단계와,
(h) 제4단계에서 얻은 전복 효소적 가수분해물과 제7단계에서 얻은 해조류 및 산야초 추출물을 혼합하는 제8단계를 포함하는 것을 특징으로 하는 전복, 해조류 및 산야초를 이용한 식품의 제조방법.(a) the first step of pretreatment of washing the abalone, removing foreign substances and removing the shell;
(b) a second step of grinding the decorated part separated in the first step by using a grinder,
(c) a third step of enzymatic hydrolysis by adding proteolytic enzyme to the milled product prepared in the second step;
(d) a fourth step of materializing the abalone enzymatic hydrolyzate by inactivating the enzyme by heat treatment of the abalone enzymatic hydrolyzate prepared in the third step and removing the remaining insoluble material;
(e) a fifth step of washing and removing foreign substances containing seaweeds containing seaweed, seaweed and kelp, and wild grasses containing bokbunja, Angelica and Ogapi;
(f) a sixth step of extracting hot water by adding 10 times of water to each of the algae and wild grasses pretreated in the fifth step;
(g) a seventh step of filtering and concentrating or drying the extract obtained in the sixth step;
(h) a method for producing food using abalone, seaweed and wild grass, comprising an eighth step of mixing the abalone enzymatic hydrolyzate obtained in the fourth step with the seaweed and wild grass extract obtained in the seventh step.
상기 제3단계는, 상기의 단백질 가수분해효소로 알카라제, 뉴트라제 프로타멕스, 플라보자임으로 이루어진 군에서 선택된 어느 하나 이상의 효소를 이용하고,
상기 제6단계는, 해조류와 산야초 추출물은 121℃에서 열수추출을 하는 것을 특징으로 하는 전복, 해조류 및 산야초를 이용한 식품의 제조방법.The method of claim 1,
The third step, using any one or more enzymes selected from the group consisting of alkalase, neutrase protamex, flavozyme as the proteolytic enzyme,
In the sixth step, seaweed and wild vinegar extract is a method of producing food using abalone, seaweed and wild grasses characterized in that the hot water extraction at 121 ℃.
상기 제8단계는 전복 효소적 가수분해물과 해조류 및 산야초 추출물을 혼합하여 액상, 과립제, 환제, 정제 중 어느 하나의 형태로 제조하는 것을 특징으로 하는 전복, 해조류 및 산야초를 이용한 식품의 제조방법.3. The method according to claim 1 or 2,
The eighth step is mixed with abalone enzymatic hydrolyzate and algae and wild grass extract to produce a form of liquid, granules, pills, tablets, abalone, seaweeds and wild vegetables.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110140666A KR101364752B1 (en) | 2011-12-22 | 2011-12-22 | Method for prepairing food using abalone, seaweed and wild plants |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110140666A KR101364752B1 (en) | 2011-12-22 | 2011-12-22 | Method for prepairing food using abalone, seaweed and wild plants |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130073008A KR20130073008A (en) | 2013-07-02 |
KR101364752B1 true KR101364752B1 (en) | 2014-02-20 |
Family
ID=48987548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020110140666A KR101364752B1 (en) | 2011-12-22 | 2011-12-22 | Method for prepairing food using abalone, seaweed and wild plants |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101364752B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102305514B1 (en) * | 2019-07-24 | 2021-09-27 | 조선옥 | Dried Aabalone and its powder |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030011464A (en) * | 2001-08-03 | 2003-02-11 | 성덕모 | Composition for healthy food carpable of removing toxic oxygen using wild plants and method for extracting wild plants |
KR100640239B1 (en) | 2006-03-15 | 2006-11-01 | 우진산업주식회사 | Method of complex globule of grinded seaweed fusiforme . ormer and complex globule fabricated by the same |
KR20090032562A (en) * | 2007-09-28 | 2009-04-01 | 이여준 | Functional drink comprising abalone extract and the preparation method of thereof |
KR20120066164A (en) * | 2010-12-14 | 2012-06-22 | 전라남도 | Process for producing abalone hydrolysate and prepairing functional food using thereof |
-
2011
- 2011-12-22 KR KR1020110140666A patent/KR101364752B1/en not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030011464A (en) * | 2001-08-03 | 2003-02-11 | 성덕모 | Composition for healthy food carpable of removing toxic oxygen using wild plants and method for extracting wild plants |
KR100640239B1 (en) | 2006-03-15 | 2006-11-01 | 우진산업주식회사 | Method of complex globule of grinded seaweed fusiforme . ormer and complex globule fabricated by the same |
KR20090032562A (en) * | 2007-09-28 | 2009-04-01 | 이여준 | Functional drink comprising abalone extract and the preparation method of thereof |
KR20120066164A (en) * | 2010-12-14 | 2012-06-22 | 전라남도 | Process for producing abalone hydrolysate and prepairing functional food using thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20130073008A (en) | 2013-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101541516B1 (en) | Mathod Manufacturing lON Mineral Using Silk worm, Muberry leaf, and Muberry twig And Health Drink Manufactured by this | |
KR101773252B1 (en) | The process of making healthcare compositions comprising fermented Dendropanax morbifera extracts and herbal medicines Abalone extracts | |
KR20150103953A (en) | Manufacturing method of fermented salt containing ginseng steaed red juice | |
KR20110077807A (en) | The producing process of functional and fermented material containing taurine and gaba by fermentation with oyster | |
CN101380128B (en) | Zhukui multifunctional health care beverage and production method thereof | |
KR20210068967A (en) | Composition for relieving and preventing hangover comprising dendropanax morbifera extract | |
KR102254420B1 (en) | Antimicrobial composition comprising the fermentation extract of medicinal or edible natural products | |
KR101364752B1 (en) | Method for prepairing food using abalone, seaweed and wild plants | |
KR102197395B1 (en) | The process of making healthcare composition for relieving and preventing alcoholic hangover comprising fermented Dendropanax morbifera extract and Capsosiphon fulvescens extracts | |
CN116726140A (en) | Shark liver peptide compound product for dispelling effects of alcohol and protecting liver and application thereof | |
KR101182039B1 (en) | The Chinese matrimony vine & Leaf Gochujang | |
CN103666940A (en) | Process for preparing purple sweet potato liquor with biological enzymolysis method | |
KR101773250B1 (en) | The manufacturing method of making healthcare compositions comprising fermented Eriobotrya japonica extracts and herbal medicines Abalone extracts | |
CN111944009B (en) | Preparation method and application of salicornia bigelovii antihypertensive peptide | |
CN107279720A (en) | A kind of mulberry leaf manual factured hollow fine dried noodles and preparation method | |
KR20220169028A (en) | Functional foods using abalone, algae, and wild vegetation that are effective in preventing or improving dementia | |
CN111296598B (en) | Composite black jerusalem artichoke sports tea beverage and preparation method thereof | |
KR101672098B1 (en) | Composition for removing hangover comprising fermented rice rinse water | |
KR20120066164A (en) | Process for producing abalone hydrolysate and prepairing functional food using thereof | |
KR101316187B1 (en) | Processing method of tomato cake and its functional product | |
CN111758870A (en) | Instant chaenomeles speciosa solid beverage and preparation method thereof | |
KR101341162B1 (en) | method manufacture and annex drink use bark pine extract | |
KR20160123552A (en) | Health drink and manufacturing method thereby | |
KR100475628B1 (en) | Healthful food on the base trepang manufacturing method | |
KR20160115205A (en) | Manufacturing method of natural nutrition soybean paste using blackbean |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |